Acelyrin price target lowered to $3 from $6 at Citi

Citi lowered the firm’s price target on Acelyrin (SLRN) to $3 from $6 and keeps a Neutral rating on the shares after the company presented Phase 1b/2 dose-finding efficacy and safety data in thyroid eye disease patients for lonigutamab and shared the trial design for the Phase 3 LONGITUDE program. The shares are weak post the disclosure on the selection of once every two weeks dosing for the Phase 3 dosing regimen and uncertainty surrounding efficacy expectations for a Phase 3 dose not tested in the Phase 1b/2 study, the analyst tells investors in a research note. Citi continues to see value in advancing lonigutamab, but anticipates the lack of catalysts ahead of Phase data in the second half of 2025, the heavy capital investment required to run two Phase 3 trials, and competitive concerns will continue to weigh on the shares.